Serum galectin-3BP as a novel marker of obesity and metabolic syndrome in Chinese adolescents

Shihan Zhen 1, Yanan Ma 2, Yanshuo Han 2, Zhongyi Zhao 2, Xuelian Yang 1, Deliang Wen 1

ABSTRACT

Introduction Childhood obesity (OB) and metabolic syndrome (MetS) have become a worldwide health problem. Comparative proteomic approaches are widely used in human OB to analyze protein changes in blood plasma. The present study determined the galectin-3 binding protein (galectin-3BP) expression level in different weight categories and assessed the associations between galectin-3BP and OB and MetS.

Research design and methods The current study included 932 Chinese adolescents 13–18 years of age. The biochemical and anthropometric variables of all the subjects were evaluated using standardized procedures. The differentially expressed proteins (DEPs) were investigated among 60 adolescents (20 normal weight, 20 overweight and 20 obese) using tandem mass tag (TMT) quantitative proteomics. The serum galectin-3BP level was measured using ELISA. The associations between galectin-3BP and OB and MetS were analyzed in 932 adolescents using multiple logistic regression analyses.

Results A significant DEP, galectin-3BP, can effectively separate the obese from the normal weight group using TMT. Adolescents in tertile 3 of galectin-3BP, when compared with adolescents in the tertile 1, were positively associated with OB (OR=3.32, 95% CI 1.79 to 6.16) and MetS (OR=3.28, 95% CI 1.30 to 8.26). The receiver operating characteristic curve for galectin-3BP in subjects with MetS indicated that the area under the curve was 0.85 (95% CI 0.79 to 0.91).

Conclusions This study confirmed an association between galectin-3BP and OB in Chinese adolescents, and galectin-3BP was also positively associated with MetS, and thus might be useful for identifying adolescents with MetS.

INTRODUCTION

Childhood obesity (OB) and metabolic syndrome (MetS) have become a worldwide health problem. The percentage of overweight and obese children has increased at an alarming rate. Between 1991 and 2014, the prevalence of overweight (OW) in Chinese children continuously increased from 5.0% to 13.2%, while the prevalence to OB increased from 1.7% to 6.8%. These large increases in the prevalence of childhood OB might greatly increase morbidity in adulthood from MetS. MetS is a group of complex metabolic disorders that affect carbohydrates, proteins, fats, and other substances in the body. As reported in a 2015 meta-analysis, MetS has an incidence of 1.8%–4.5% in Chinese adolescents; more specifically, the incidence follows the order of OB>OW>normal weight (NW). Typically, an increase in MetS incidence increases morbidities, including cancers, arthritis, diabetes, and cardiovascular diseases. Therefore, it is essential to identify biomarkers to predict MetS risk among adolescents, which in turn will facilitate improved management of MetS-associated public health problems.

Tandem mass tag (TMT) is a protein quantitative technique based on tandem mass spectrometry that is widely used in screening the biomarkers for prognosis and diagnosis. TMT has been used to analyze the proteomic changes of obese individuals. Consequently, the clinical proteomic strategy facilitates a comprehensive understanding of serum factors that are involved in childhood OB
and sheds light on changes in the signal transduction pathways. Determining the proteomic changes in childhood OB may contribute to a better understanding of the pathogenesis underlying MetS. Specifically, serum proteomic analysis serves as an efficient way to identify protein biomarkers to recognize, diagnose, monitor and treat various disorders, such as OB and MetS.10 11

Galectin-3 binding protein (galectin-3BP), also referred to as M2BP, is a largely glycosylated protein containing seven N-linked glycosylation sites.12 Galectin-3BP, which has multimeric forms, has several targets, such as galectin-1, galectin-3, galectin-7 and extracellular matrix.12 13 The full complement of galectin-3BP biological activities is not known, but it is known that galectin-3BP participates in cell growth, inflammation, cellular adhesion, and an increase in visceral fat deposition.13–15 Additionally, it has been reported that galectin-3BP expression is detected among different cell types, such as mucosal or glandular epithelium and hematopoietic cells16 17; galectin-3BP is highly expressed within serum in patients with hepatitis, non-alcoholic fatty liver disease, and autoimmune disease.15 17 Plasma galectin-3BP has been reported to be elevated in obese individuals18 19 and individuals with symptoms of MetS.19–21 To the best of our knowledge, however, most previous studies involved adults; the variations in galectin-3BP expression among obese adolescents or adolescents with MetS have rarely been reported.

Although several studies have reported increased levels of galectin-3BP in the obese individuals,18 19 few studies have investigated the relationship in adolescents. The association between galectin-3BP and MetS has not been established. By adopting the proteomic method in a well-characterized Chinese study, we investigated the differentially expressed proteins (DEPs) among adolescents with NW, OW, and OB, and investigated the associations between galectin-3BP and OB and MetS.

METHODS

Clinical information

An observational, school-based, case–control study was conducted to estimate OB from a multicenter prospective cohort (Huanggu District Middle and Primary School Student Physical Fitness Monitoring).22 This cohort was established to investigate the health outcomes, weight status, and growth status, and to explore the genetic–environmental interactions of primary and middle-school children and adolescents in Northeast China. For TMT quantitative proteomics, a total of 60 representative adolescents meeting those predetermined inclusion criteria were enrolled. Then, 20 samples from each group that had the equivalent serum volumes were blended. Subsequently, proteins with high abundance were depleted from the resulting mixed serum samples. After anthropometry measurements and blood sample analyses were completed, a total of 932 adolescent students (13–18 years of age) were eligible to participate. The participants were used to verify the reliability of TMT. A flowchart showing the participant selection process is provided in online supplemental figure S1.

Weight and height were determined in accordance with the WHO recommended normalized techniques. In addition, adolescents with OB and OW were determined based on their sex and age in accordance with the Body Mass Index (BMI) growth references for 5–19 years formulated by the WHO. MetS was diagnosed in accordance with the Society of Pediatrics of Chinese Medical Association report on MetS in the adolescent population.23 Participants and their parents had provided written informed consent to perform venipuncture and were informed about the intended use of the sample.

TMT labeling and grouping

TMT labeling reagent (20 μL) was added to every peptide solution for 1 hour of reaction. Typically, peptide was labeled using a TMT 10-plex kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA) in the TMT 10-plex Label Reagent Set in accordance with manufacturer’s instructions.

Sixty samples were randomized into six groups for liquid chromatography with tandem mass spectrometry and TMT analyses. The control participants had matched sex, ethnicity, and maternal age (online supplemental figure S1). Peptides from the adolescent with OB, OW and NW were labeled using TMT-126, TMT-127N, TMT-127C, TMT-128N, TMT-128C and TMT-129N reagents (TMT; Thermo, Pierce Biotechnology, Rockford, Illinois, USA).

Data analyses

Workflow of Proteome Discoverer software V.1.3 (Thermo Fisher Scientific, San Jose, California, USA) was used to process all mass spectrometry (MS) information. Thereafter, the Proteome Discoverer extract feature was used to process those data about tandem mass spectrometry spectra using the Mascot retrieval function in the workflow. In addition, a human database (201709, time files compressed): Tue Nov 28 15:06:52 2017 containing 71,591 sequences was adopted to retrieve those tandem mass spectra.

The Proteome Discoverer automatically analyzes results statistically, which also adopts the unique peptides for accurately calculating the relative protein level. The top one peptide rank filters and high peptide confidence were employed to extract protein and peptide data. In addition, the decoy database was used to analyze peptide sequences, so as to calculate the false discovery rate (FDR). Then, the percentage variability and the mean ratio were adopted to quantify proteins in which several peptides were found within a single protein.

Functional analyses for those DEPs

The UniProt-GOA database was used to perform the analysis. Specifically, there are three Gene Ontology (GO) annotation classes, including molecular function (MF), cellular compartment (CC) as well as biological process (BP).
every category, DEP enrichment was tested through the two-tailed Fisher’s exact test among the proteins identified. The normalized FDR control approach was used to correct multiple hypothesis testing, and those GO terms that had an adjusted p value of <0.05 were considered significant.

In addition, protein pathways were annotated using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. First of all, KAAS, the online service tool of KEGG, was used to annotate protein descriptions in the KEGG database. Then, the annotation results were mapped onto the KEGG database with the KEGG mapper, another online service approach of KEGG.

Biomarker verification

Human galectin-3BP ELISA Kit (EK1240, Cambridge, Ontario, Canada) was used to examine galectin-3BP through the ELISA strictly following manufacturer protocols. In addition, the original standards provided by the kit were adopted to dilute gradually, and biomarker concentrations within specific samples were calculated using standard curves. Besides, the serum galectin-3BP (dilution, 1:500) was detected through the human galectin-3BP ELISA kit, and the minimal detectable dose was 156 pg/mL. Each sample was tested in duplicate.

Definition of the galectin-3BP group

The participants were divided into three groups according to the tertiles of the galectin-3BP concentration. Participants were divided into ‘tertile 1’, ‘tertile 2’ and ‘tertile 3’ groups. An increased concentration was assumed from tertiles 1–3.

Statistical analysis

The relative expression levels of protein expression among adolescents with OB, OW, and NW were compared with identified DEPs. Specifically, proteins were deemed to show differential expression when TMT ratios in the OB or OW serum samples were <0.67 or >1.5 in comparison with adolescents with NW.

Descriptive information was presented in mean and SD for Gaussian distribution and medians together with the upper and lower quartiles for non-Gaussian distribution. Multiple logistic regression model was used to determine the relationships between galectin-3BP and weight status and MetS. Then, logistic regression modeling and the receiver operating characteristic (ROC) curves were used to jointly detect candidate biomarkers and analyze the individual roles. A p value of <0.05 indicated statistical significance. In the current work, both SPSS V.25.0 and STATA V.13.0 were used to analyze statistically. Meanwhile, R Studio (R Studio, USA) and GraphPad Prism V.5.0 (GraphPad, La Jolla, California, USA) were used for graph preparation.

RESULTS

Participant characteristics and protein identification based on TMT

A total of 60 serum samples were collected from adolescents with OB, OW, and NW matched for sex and age

![Figure 1](http://drc.bmj.com/)

Figure 1: Detailed functional classifications of the identified proteins. (A–C) GO analysis was performed to identify the functional significance for each screened protein. (D–F) KEGG pathway analysis was used to elucidate the enrichment pathway. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
in the current work (online supplemental table S1). Online supplemental figure S2 shows validation of MS data. In total, 680 proteins were examined using TMT MS analyses on serum samples among adolescents with different weight states (online supplemental figure S3). In the current work, 177 proteins that had an average fold change in expression level of ±1.5 were recognized to be the DEPs. Among the 177 proteins, 85 proteins were shown to be significantly differentially expressed in OW samples relative to NW. The DEPs were selected in the current work to effectively separate the OB and OW groups from the NW group. Additionally, results of hierarchical clustering proved the reasonability of the asscreened DEPs.

Annotation analyses for DEPs (GO+KEGG)
GO analysis was conducted to identify the functional significance for each screened protein. Figure 1A–C presents the functional classifications for each ascreened protein. Unlike the ascreened proteins, a few of the proteins (n<10) were associated with the BP classifications of chromosome organization (n=9) and chromatin organization (n=8) in the adolescents with OB compared with the adolescents with NW. In the cellular protein classification, organelle (n=42), macromolecular complex (n=26), intracellular organelle with no membrane binding (n=22), and organelle with no membrane binding (n=22) were the major CCs. For the MF classification, heterocyclic compound binding (n=21) and nucleic acid binding (n=14) were the primary functional categories for those reduced proteins (figure 1C).

According to KEGG pathway analysis, a total of 69, 146 and 69 KEGG pathways were clustered for the OW/NW, OB/OW, and OB/NW groups, respectively. Figure 1D–F provided a panoramic view of the systemic lupus erythematosus (SLE) pathway, the metabolic pathway, the hypertrophic cardiomyopathy (HCM) pathway, and the dilated cardiomyopathy (DCM) pathway, and they were primarily involved DEPs. Relative to the NW group, the elevated proteins in adolescents with OB were mainly involved in the SLE (5) and metabolic pathway (5) in figure 1F, whereas compared with the OW group, the elevated proteins of the adolescents with OB were mainly involved in the HCM (4) and DCM (4) pathways, as shown in figure 1E.

Verification of the differential expression of galectin-3BP
According to the intersection analysis within three comparative groups through hierarchical clustering analysis (figure 2) and KEGG network analysis, there were altogether 26 DEPs (online supplemental table S2). The aforementioned findings were synthesized, such as the ratio of fold change, as well as KEGG and GO analysis, and it was shown that, a majority of significant DEPs were related to the metabolic pathway.

Moreover, the intersection analysis identified 26 potential proteins for hierarchical clustering analysis, 11 of which were excluded because they were not involved in the elevated proteins. The serum levels of serum amyloid A, C reactive protein, plasminogen activator inhibitor-1, and alcohol dehydrogenase have been previously investigated in children or adolescents with OB. Another three proteins were identified to contain the non-gradient change among the three weight groups, including two overlapping with the included proteins from the same description, two forming different cytoskeletal types, and one belonging to the protein fragment. Moreover, the galectin-3BP was selected to carry out further study, since neither charged multivesicular body protein 6 nor inhibin beta E chain commercial kit was available. Figure 2 presents flowcharts to obtain these in the trial.

Associations between galectin-3BP and OB or MetS
Table 1 shows the feature for the whole participants. The participants were classified based on the tertile for

![Figure 2](http://drc.bmj.com)  Flowcharts to obtain intersection in the trial: the 26 protein expressions in 60 adolescents’ plasma and the screening details of protein based on intersection analysis.
galectin-3BP expression. Participants in the highest tertile of galectin-3BP were more likely to be OB and MetS. After adjusting for confounders, adolescents in tertiles 3 and 2 of the galectin-3BP level had higher odds of having OB than adolescents in tertile 1 (OR=3.32, 95% CI 1.79 to 6.16 for tertile 3; OR=2.48, 95% CI 1.32 to 4.65 for tertile 2), adolescents in tertile 3 of the galectin-3BP level had higher odds of MetS than those in tertile 1 (OR=3.28, 95% CI 1.30 to 8.26 for tertile 3). The results are shown in table 2. The area under the curve was 0.85 (95% CI 0.79 to 0.91). The results are shown in figure 3.

**DISCUSSION**

This study examined the heterogeneity of protein expression among the Chinese adolescents with or without OB/MetS, and to validate galectin-3BP expression in samples collected from the study population. Galectin-3BP served as a novel biomarker screened to be related to being OB or having MetS. Indeed, this study suggested that participants in the highest tertile of galectin-3BP level were more likely to be OB and MetS, and they were consistent with findings obtained from prior research on adults.18 19 Galectins have been shown to be essential in regulating cell growth and adhesion, triggering or inhibiting cell apoptosis,12 which may stimulate preadipocytes to differentiate into lipid-loaded adipocytes, enhance the proliferation of adipocytes and result in closer relationship with OB.27 Moreover, several animal studies have shown that galectins may serve as the factors to positively regulate OB induced by high-fat diet, and they are increased

---

**Table 1 Characteristics of the study population according to tertiles of galectin-3BP level**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Tertile 1 (n=310)</th>
<th>Tertile 2 (n=311)</th>
<th>Tertile 3 (n=311)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>16.27 (1.04)</td>
<td>16.27 (1.02)</td>
<td>16.05 (0.91)</td>
</tr>
<tr>
<td>Girls, n (%)</td>
<td>144 (46.45)</td>
<td>148 (47.59)</td>
<td>190 (61.09)</td>
</tr>
<tr>
<td>Anthropometry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI z-score, mean (SD)</td>
<td>0.06 (1.17)</td>
<td>0.43 (1.36)</td>
<td>0.65 (1.36)</td>
</tr>
<tr>
<td>Waist circumference, mean (SD)</td>
<td>71.95 (8.60)</td>
<td>75.00 (11.54)</td>
<td>75.97 (12.01)</td>
</tr>
<tr>
<td>Weight status, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NW</td>
<td>250 (80.65)</td>
<td>204 (65.59)</td>
<td>181 (58.20)</td>
</tr>
<tr>
<td>OW</td>
<td>40 (12.90)</td>
<td>61 (19.61)</td>
<td>73 (23.47)</td>
</tr>
<tr>
<td>OB</td>
<td>20 (6.45)</td>
<td>46 (14.79)</td>
<td>57 (18.33)</td>
</tr>
<tr>
<td>MetS outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MetS, n (%)</td>
<td>8 (2.58)</td>
<td>15 (4.82)</td>
<td>23 (7.40)</td>
</tr>
<tr>
<td>Center obesity, n (%)</td>
<td>48 (15.48)</td>
<td>92 (29.58)</td>
<td>106 (34.08)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>69 (22.62)</td>
<td>66 (21.22)</td>
<td>82 (26.37)</td>
</tr>
<tr>
<td>Hyperglycemia, n (%)</td>
<td>3 (0.97)</td>
<td>5 (1.61)</td>
<td>5 (1.61)</td>
</tr>
<tr>
<td>High_TG, n (%)</td>
<td>26 (8.39)</td>
<td>30 (9.65)</td>
<td>26 (8.36)</td>
</tr>
<tr>
<td>Low_HDL-C, n (%)</td>
<td>35 (11.29)</td>
<td>43 (13.83)</td>
<td>48 (15.43)</td>
</tr>
<tr>
<td>Laboratory examinations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FPG (mmol/L), median (Q1–Q3)</td>
<td>4.28 (4.0–4.56)</td>
<td>4.25 (3.96–4.53)</td>
<td>4.31 (4.05–4.6)</td>
</tr>
<tr>
<td>TG (mmol/L), median (Q1–Q3)</td>
<td>0.71 (0.53–0.98)</td>
<td>0.76 (0.55–1.04)</td>
<td>0.80 (0.59–1.07)</td>
</tr>
<tr>
<td>ALT (U/L), median (Q1–Q3)</td>
<td>10 (8–16)</td>
<td>10 (8–17)</td>
<td>10 (8–17)</td>
</tr>
<tr>
<td>AST (U/L), median (Q1–Q3)</td>
<td>15 (13–18)</td>
<td>16 (13–19)</td>
<td>15 (13–18)</td>
</tr>
<tr>
<td>ALP (U/L), median (Q1–Q3)</td>
<td>96 (76–126)</td>
<td>93 (77–117)</td>
<td>93 (74–126)</td>
</tr>
<tr>
<td>GGT (U/L), median (Q1–Q3)</td>
<td>16 (13–20)</td>
<td>16 (13–22)</td>
<td>16 (13–22)</td>
</tr>
<tr>
<td>C1q (mg/L), median (Q1–Q3)</td>
<td>176.0 (156.6–201.4)</td>
<td>177.6 (154.6–200.2)</td>
<td>184.5 (167.5–209.5)</td>
</tr>
<tr>
<td>HDL-C (mmol/L), median (Q1–Q3)</td>
<td>1.31 (1.14–1.50)</td>
<td>1.30 (1.11–1.51)</td>
<td>1.28 (1.13–1.51)</td>
</tr>
<tr>
<td>LDL-C (mmol/L), median (Q1–Q3)</td>
<td>2.08 (1.70–2.50)</td>
<td>2.12 (1.79–2.52)</td>
<td>2.19 (1.80–2.58)</td>
</tr>
<tr>
<td>Apolipoprotein A1 (g/L), median (Q1–Q3)</td>
<td>1.30 (1.21–1.42)</td>
<td>1.31 (1.20–1.41)</td>
<td>1.32 (1.19–1.45)</td>
</tr>
<tr>
<td>Apolipoprotein B (g/L), median (Q1–Q3)</td>
<td>0.61 (0.52–0.72)</td>
<td>0.63 (0.54–0.73)</td>
<td>0.66 (0.56–0.76)</td>
</tr>
<tr>
<td>Small dense low-density lipoprotein cholesterol (mmol/L), median (Q1–Q3)</td>
<td>0.42 (0.33–0.52)</td>
<td>0.42 (0.33–0.51)</td>
<td>0.43 (0.34–0.53)</td>
</tr>
</tbody>
</table>

ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, Body Mass Index; FPG, fasting plasma glucose; galectin-3BP, galectin-3 binding protein; GGT, gamma-glutamyl transferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; NW, normal weight; OB, obesity; OW, overweight; TG, triglyceride.
Taken together with our results, galectin-family 3BP increases adipocyte differentiation. Galectin-3BP is related to OW or OB compared with NW. Originally, elevated galectin-3BP might be a novel biomarker related to OB. Furthermore, they also show that galectin-3BP is positively associated with the lipoprotein level. Challa et al reported that several adipokines are able to regulate the differentiation of adipocytes, and knockdown of galectin-3BP in preadipocyte cell lines increases adipocyte differentiation. Taken together with our results, galectin-3BP may also affect proliferation or other functions other than differentiation in adipose tissue, then influence human OB. Galectin-3BP might be a novel biomarker related to OB.

Nonetheless, the precise activity and functions during metabolic control should be elaborated in future studies. MetS is diagnosed when central OB plus any two of four other factors; however, the association between galectin-3BP level and MetS risk factors is still unknown. In the present study, we reported that the galectin-3BP level had a positive association with MetS among adolescents. Some mechanisms may account for such a relationship. First, galectin-3BP is correlated with components of visceral fat and levels of lipoprotein. Roelofsen et al reported that galectin-3BP is secreted from visceral adipose tissues. Typically, the increase in visceral fat is verified to further boost insulin resistance; thus, MetS is probably induced by insulin resistance caused by galectin-3BP. Second, Niinaga et al had confirmed the association between galectin-3BP and adiponectin through reconstituted proteins in vitro. Hypoadiponectinemia is closely associated with hypertension, dyslipidemia, diabetes mellitus, and visceral fat OB related to MetS. Third, inflammation is also a mechanism to account for such associations. Galectin-3BP is implicated in inflammatory distress, immune response, and chronic low-grade inflammation. It is widely reported that inflammation is essential to the pathogenesis underlying MetS. Galectin-3BP is significantly positively associated with inflammatory markers, including interleukin (IL)-6, IL-1β, and tumor necrosis factor alpha, and together participate in MetS pathogenesis related to galectin-3BP, since inflammation may probably result in insulin resistance. Finally, galectin-3BP refers to a large oligomeric glycoprotein, and it has been recognized to be the galectin-3 ligand. A previous study showed that the galectin-3 level is correlated with visceral fat, lipoprotein level, glucose homeostasis and even MetS. Therefore, it is possible that galectin-3BP may affect the distribution of body fat, gluconeogenesis, hyperglycemia, and lipolysis. Such an association leads to imbalanced lipid metabolism, while

---

**Table 2** Multivariable adjusted ORs and 95% CI for OW, OB and MetS across tertiles of galectin-3BP level

<table>
<thead>
<tr>
<th></th>
<th>Tertile 1 (n=310)</th>
<th>Tertile 2 (n=311)</th>
<th>Tertile 3 (n=311)</th>
<th>P value for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OW+OB</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age-adjusted</td>
<td>2.21 (1.53 to 3.19)</td>
<td>2.87 (2.00 to 4.13)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Multiple-adjusted</td>
<td>2.38 (1.55 to 3.67)</td>
<td>2.95 (1.92 to 4.54)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td><strong>OB</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age-adjusted</td>
<td>2.53 (1.46 to 4.39)</td>
<td>3.13 (1.83 to 5.36)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Multiple-adjusted</td>
<td>2.48 (1.32 to 4.65)</td>
<td>3.32 (1.79 to 6.16)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td><strong>MetS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age-adjusted</td>
<td>1.92 (0.80 to 4.61)</td>
<td>2.85 (1.25 to 6.48)</td>
<td>0.011</td>
<td></td>
</tr>
<tr>
<td>Multiple-adjusted</td>
<td>1.58 (0.59 to 4.24)</td>
<td>3.28 (1.30 to 8.26)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Multiple-adjusted model: adjusted for age (in years), sex (boys vs girls), ALT (U/L), AST (U/L), ALP (U/L), and GGT (U/L). P value for trend was obtained by adjusting tertiles of galectin-3BP level as a continuous variable. P values of <0.05 are in bold.

**ROC curves of tertiles of galectin-3BP level for MetS.** The area under the ROC curve was 0.85 (95% CI 0.79 to 0.91). Galectin-3BP, galectin-3 binding protein; MetS, metabolic syndrome; OB, obesity; OW, overweight.
this may thereby result in a reduced capacity for maintaining the metabolic homeostasis.

Indeed, this study was the first to report an association between galectin-3BP and MetS in Chinese adolescents. Typically, we should not overlook the value of galectin-3BP in predicting the risk of MetS when used in combination with other biomarkers due to the low cost for detection. Nonetheless, certain limitations should also be noted in this study. First, the cross-sectional study design limited the ability to indicate the causality in the association. Therefore, prospective studies should be carried out for verifying the causality between MetS and galectin-3BP in adolescents. Second, all adolescents were enrolled from the same city, which might not necessarily represent the general Chinese adolescent population. Third, we did not use other adipokine (adiponectin or leptin) levels. We may compare galectin-3BP with adiponectin in terms of the ROC curve for MetS in the future. Finally, this work did not consider the pubertal stage among those recruited adolescents. Nevertheless, sex and age were adopted as the confounders when carrying out multiple regression analysis, thus minimizing the impacts of the limitation.

This study suggests that elevated galectin-3BP expression might serve as a marker for predicting MetS among Chinese adolescents. In conclusion, findings in this study demonstrated that an elevated galectin-3BP was related to overweight adolescents and an even greater association with adolescents with OB. Galectin-3BP level had a positive association with MetS. This finding is particularly important for adolescents, who have an increasing risk for OB and MetS. Galectin-3BP can predict the risk of MetS when used in combination with other biomarkers due to its low cost for detection. Nonetheless, more studies should be carried out to clarify the galectin-3BP role as a biomarker in MetS.

Acknowledgements
The authors thank the participants in the study.

Contributors
YM and DW conceived and designed the study. SZ, YH, ZZ and XY collected, managed, and analyzed the data. SZ and YH drafted the manuscript. All authors read and approved the final version of the manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (71774173).

Competing interests
None declared.

Patient consent for publication
Not required.

Ethics approval
The study was approved by the ethics committee of China Medical University (2017) (055).

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available upon reasonable request.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iD
Shihian Zhen http://orcid.org/0000-0003-3248-2684

REFERENCES


